A Review on New Drug Regimens in the Treatment of Multidrug-Resistant Tuberculosis

A major worldwide health problem, multidrug-resistant tuberculosis (MDR-TB) reflects resistance to at least isoniazid and rifampicin, the first-line anti-TB treatments. Various elements cause this syndrome, including inadequate or incomplete treatment adherence, antibiotic abuse, and direct transmission of resistant Mycobacterium tuberculosis strains. Worldwide, MDR-TB presents a major difficulty for efficient tuberculosis control initiatives. Often, the clinical presentation of MDR-TB is indistinguishable from that of drug-sensitive tuberculosis. Common symptoms are chronic cough, fever, night sweats, tiredness, chest discomfort, and notable weight loss. These symptoms might impair the quality of life, postpone diagnosis, and make prompt treatment start more difficult. Compared to drug-sensitive TB, MDR-TB treatment is noticeably more complicated. It incorporates second-line anti-TB medications, which frequently have longer treatment durations (18–24 months), more adverse effects, and inferior efficacy. Novel regimens like the BPALM regimen and bedaquiline-based therapies are examples of recent developments that have showed promise in shortening treatment durations and enhananc. In order to address MDR-TB, this review highlights the urgent need for improved diagnosis methods, better treatment regimen adherence, and all-encompassing international policies. Governments, medical professionals, and communities must work together to solve this changing health catastrophe and lessen the global burden of MDR-TB.